Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0344307 (
analgesia
)
28,200
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The effect of i.p. administration of kappa-opioid receptor agonists, bremazocine, tifluadom and U-50,488H on morphine (8 mg/kg i.p.)-induced
analgesia
in morphine-naive and morphine tolerant male Sprague-Dawley rats was determined using the tail-flick test. The tolerance to morphine in the rats was induced by s.c., implantation of six morphine pellets during a 7-day period. Implantation of morphine pellets resulted in the development of tolerance as evidenced by the decrease in the analgesic response to morphine when compared to placebo pellets implanted rats. Bremazocine (0.3, 1.0 and 3.0 mg/kg) and U-50,488H (16 mg/kg) antagonized morphine-induced
analgesia
in morphine-naive rats while tifluadom (8 and 16 mg/kg) potentiated the effect. In morphine-tolerant rats, bremazocine (3 mg/kg) and U-50,488H (16 mg/kg) potentiated morphine-induced
analgesia
.
Tifluadom
at any of the doses had no effect on morphine-induced
analgesia
in morphine-tolerant rats. These results provide evidence that different kappa-opioid agonists modify morphine-induced
analgesia
differentially in morphine-naive and morphine-tolerant rats.
...
PMID:Effect of kappa-opioid receptor agonists on morphine analgesia in morphine-naive and morphine-tolerant rats. 285 74
Suppression of evoked potentials of the EEG are indicators of
analgesia
.
Tifluadom
induces latency changes which are reversed by the kappa-antagonist Mr 2266. Naloxone reverses peak suppression which indicates an additional interaction with the my-opioid-receptor. The specific benzodiazepine antagonist Ro 15-1788 is not effective in reversing peak-changes. Therefore nociceptive stimuli are modulated by tifluadom not only through the interaction with kappa- but also with my-opioid-receptors.
...
PMID:Tifluadom (KC 5103) induces suppression and latency changes on somatosensory evoked potentials which are reversed by opioid antagonists. 631 8